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Abstract
Background: Voriconazole is approved for treatment of invasive aspergillosis and other invasive fungal infections,
but the role for therapeutic drug monitoring (TDM) is not clear.
Methods: We performed a retrospective cohort study of patients at the University of Washington Medical Center
and Fred Hutchinson Cancer Research Center from 2007–2009. We compared the effect of therapeutic levels on
clinical outcomes and evaluated the relationship between drug levels and adverse events.
Results: A total of 108 patients had voriconazole TDM performed, of whom 84 (77.8%) had a hematologic
malignancy and 47 (43.5%) had undergone hematopoietic stem cell transplantation. The primary reasons for
treatment were presumed pulmonary aspergillosis (n = 83, 76.8%), other invasive mould infections (n = 13, 12.0%)
and candidiasis (n = 9, 8.3%). There was a high degree of variability in voriconazole drug levels among patients
(r2 = 0.01; range, <0.10 - 20 mg/L). Of the 46 patients with proven or probable invasive fungal disease, 25 (54.3%)
achieved partial or complete response to therapy. There was no significant relationship between therapeutic drug
levels and achievement of complete or partial response at 12 weeks (OR 0.29, 95% CI: 0.05-1.34) or radiologic response
(OR 1.46, 95% CI: 0.32-7.83). Overall, 45 (41.7%) patients experienced adverse events. Voriconazole levels > 5.5 mg/L
were not associated with increased incidence of encephalopathy (OR 3.08, 95% CI 0.79-11.0) or hepatotoxicity
(OR 2.45, 95% CI 0.49-10.1).
Conclusions: Voriconazole therapeutic drug levels were not associated with improvement in clinical outcomes
among patients with proven or probable invasive fungal disease. We also did not find an association between
supratherapeutic drug levels and hepatoxicity or encephalopathy. It is possible that the utility of voriconazole
therapeutic drug monitoring to improve clinical efficacy or decrease adverse events may be limited to a subset of
high-risk patients.
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Background
Invasive fungal infections (IFIs) are associated with high
morbidity and mortality, particularly among immunocom-
promised patients. Voriconazole therapy is used for treat-
ment of IFIs and is the drug of choice for treatment of
invasive aspergillosis [1-3], although it is associated with
hepatotoxicity and central nervous system adverse effects
[4,5]. Drug levels are highly variable due to nonlinear
pharmacokinetics and depend on many additional factors
including patient age, presence of genetic polymorphisms
that affect drug metabolism, and use of concomitant
medications [6-9]. Prior observational studies suggest that
monitoring of voriconazole drug levels predicts response,
decreases adverse events among patients with invasive
fungal infections, and may improve outcomes [7,10-13].
Specifically, they have found a role for a therapeutic
concentration range of 1.0 to 5.5 mg/L to maximize
therapeutic efficacy and minimize adverse events [10].
However, other factors also influence clinical outcomes,
including immune status of the host, patient age, surgical
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resection of infected tissue, and co-morbidities [14-19]. A
recent randomized controlled trial at a single center in
Korea comparing the use of routine TDM with non-TDM
for invasive fungal infections showed no difference in ad-
verse events with and without drug monitoring [20]. The
investigators concluded that among those patients in
whom TDM was performed there was a significant
reduction in discontinuation of antifungal therapy and
improvement in achievement of complete or partial
clinical response. Expert guidelines do not contain spe-
cific recommendations for therapeutic drug monitoring
although they suggest that plasma drug levels may be
useful in cases of therapeutic failure or potential drug
toxicity [1]. We performed a retrospective cohort study of
patients at our institution who had therapeutic drug moni-
toring (TDM) of their voriconazole therapy. We hypothe-
sized that therapeutic drug levels were associated with
improved clinical outcomes, and supratherapeutic levels
would be associated with adverse events, in particular
neurotoxicity and hepatoxicity in our patient population.
Materials and methods
Ethics statement
This protocol was approved by the University of
Washington School of Medicine Institutional Review
Board. Written consent was given by the patients for
their information to be stored in the hospital database
and used for research.
Patients
Using pharmacy records, we identified all consecutive in-
patients and outpatients at the University of Washington
Medical Center, Harborview Medical Center, and the
Seattle Cancer Care Alliance (all in Seattle, Washington,
USA) who were treated with intravenous or oral voricona-
zole therapy and had drug level monitoring performed be-
tween July 1, 2007 and July 31, 2009. We excluded
patients under 18 years of age and those on voriconazole
therapy who did not have TDM performed.
Methods
We performed electronic chart review of all patients in-
cluded in our study. The European Organization for
Research and Treatment of Cancer and Mycoses Study
Group (EORTC/MSG) guidelines were used for classifica-
tion of proven, probable, or possible invasive fungal infec-
tions [21]. In all patients, baseline sociodemographic data,
clinical characteristics, presence of adverse events, clinical
outcomes, timing, dose, and method of administration of
voriconazole (intravenous or oral) and frequency and tim-
ing of TDM were recorded. Voriconazole drug levels were
measured using validated high-pressure liquid chromatog-
raphy tandem mass spectrometry assays at the Mayo
Clinic (Mayo Medical Laboratories, Rochester, MN) [22].
We defined subtherapeutic levels as < 1.0 mg/L, thera-
peutic levels as 1.0-5.5 mg/L, and supratherapeutic levels
as > 5.5 mg/L [10]. Clinical outcomes were assessed using
clinical, radiologic, and microbiologic criteria at 6 and
12 weeks from start of therapy and categorized as
complete response to therapy, partial response to therapy,
progression of disease or no response to therapy. This
final category included those who died, did not respond
to therapy, or had cessation of therapy due to adverse
drug events. Neutropenia was defined as an absolute
neutrophil count (ANC) less than 1500/mm3. We de-
fined hepatoxocity as AST/ALT >5x upper limit of nor-
mal or alkaline phosphatase/total bilirubin > 3× upper
limit of normal [10]. We defined renal failure as a cre-
atinine increase of 0.3 mg/dL in 48 hours [10]. We de-
fined use of combination antifungals as administration
of micafungin, caspofungin, or amphotericin B in conjunc-
tion with voriconazole.
Data were recorded using Project Redcap and analyzed
using Stata 11.0 (StataCorp, College Station, TX) and
SAS version 9.1 (SAS Institute, Inc., Cary, NC) [23]. Cor-
relation coefficients were calculated for the relationship of
drug level to initial voriconazole dose. Median of first, sec-
ond, and third drug levels were compared using the
Kruskal-Wallis test. Fisher’s exact, X2 tests, and t-tests
with unequal variance were used to compare dosing char-
acteristics and response to therapy in patients with drug
levels < 1.0 mg/L versus ≥1.0 mg/L and to compare ad-
verse drug events in patients with drug levels ≤5.5 mg/L
versus >5.5 mg/L. Among patients with proven or prob-
able disease, the probabilities of therapeutic outcomes
were summarized using cumulative incidence estimates
and compared using the log-rank test where death or
progression to disease were considered as competing
risks among patients with and without therapeutic drug
levels (<1.0 mg/L versus ≥1.0 mg/L). The presence of
baseline confounders was compared in these two groups
using t-tests with unequal variance.
Results
Altogether, 108 patients had voriconazole TDM performed
(Table 1) between 2007 and 2009. Fifty-nine (54.6%) of pa-
tients were male. Eighty-five (78.7%) were white, seven
(6.5%) were Asian, and five (4.6%) were African-American.
Seventy-six patients (70%) were inpatient at the University
of Washington and 29 were outpatients (27.1%). Eighty-
four (77.8%) patients had a hematologic malignancy, of
whom 47 (55.9%) had undergone hematopoietic cell trans-
plantation. Of the transplants performed, 21 (43.8%) were
matched unrelated allogeneic stem cell transplants, 14
(29.2%) were matched related allogeneic stem cell trans-
plants, seven (14.6%) were mismatched unrelated allogeneic
stem cell transplants, and six (12.5%) were autologous stem
cell transplants. Twenty-eight patients had a diagnosis of
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graft versus host disease. Among patients who were
neutropenic at the start of voriconazole therapy (n = 37),
the median duration of neutropenia was 37 days [18, 56].
The primary reasons for treatment were suspected or con-
firmed pulmonary aspergillosis (n = 83, 76.8%), other inva-
sive fungal infections (n = 13, 12.0%), candidiasis (n = 9,
8.3%) and febrile neutropenia (n = 9, 8.3%). Other fungal
organisms included Fusarium (n = 2), Absidia (n = 1),
Alternaria (n = 1), Saccharomyces (n = 1), Scedosporium
(n = 1), Ascomyctes (n = 1), Rhizopus (n = 1), Pseudoalles-
cheria (n = 1), and Paecilomyces (n = 1).
Twenty-one (19.4%) patients received concomitant ta-
crolimus therapy, 47 (43.5%) received proton-pump inhibi-
tors, and nine (8.3%) received additional antifungal therapy
with micafungin, caspofungin, and/or amphotericin B. The
median weight at start of voriconazole therapy was 71.3 kg
(range, 60.5-85.8 kg).
The median duration of voriconazole therapy (n = 85)
was 35 days (range, 13–92 days) (Table 2). All patients had
at least one drug level checked after initiation of therapy,
51 patients had at least two drug levels, and 26 patients
had at least three drug levels. There was no significant
difference between median initial level (2.4 mg/L; range,
0.7 - 3.8 mg/L), second level (2.0 mg/L; range, 0.5 -
3.5 mg/L), or third level (1.4 mg/L; range, 0.6 - 4.2 mg/L)
(P = 0.55, Figure 1). In patients in whom the date of
voriconazole initiation was recorded (n = 100), the median
time between start of voriconazole therapy and initial drug
level was 11 days (range, 3–164 days), with the first drug
level checked at least two days after initiation of therapy.
Among the 64 patients for whom data were available, we
found that the median time between voriconazole dose
administration and drug level testing was 11.3 hours
(range, 8.9-12.0 hours) and that 31% of levels were
checked 10–12 hours after the last voriconazole dose.
There was no correlation between initial drug level and
weight-adjusted voriconazole dosage (r2 = 0.01; Figure 2).
When a range of 1.0-5.5 mg/L was considered thera-
peutic, 32 patients (29.6%) had subtherapeutic initial
drug levels, 64 (59.3%) had therapeutic drug levels, and
12 (11.1%) had supratherapeutic levels. Among patients
with subtherapeutic initial drug levels, 20 had a second
level checked, and 10 (50%) of the second levels remained
subtherapeutic. Among patients with supratherapeutic ini-
tial drug levels, five had a second drug level drug checked,
and four (80%) remained supratherapeutic.
Eight (7.4%) patients had proven invasive fungal disease,
38 (35.1%) had probable disease, and 43 (39.8%) had pos-
sible disease. Overall, 43 (39.8%) patients achieved partial
or complete response to therapy at 12 weeks, while 18
(16.7%) had invasive fungal disease progression. In the
subset of patients with proven or probable invasive fungal
disease (n = 46), 22 (47.8%) achieved partial or complete
Table 1 Sociodemographic and clinical characteristics of
patients receiving voriconazole TDM between 2007-2009
Variable Patients with voriconazole drug
monitoring [n, (%)]
Number of patients 108
Median Age (IQR) 53 (38–64)
Sex, % male 59 (54.6%)
Underlying condition
Hematopoietic stem cell transplant 47 (43.5%)
Hematologic malignancy without a
stem cell transplant
37 (34.3%)
Solid organ transplantation 10 (9.3%)




Invasive pulmonary aspergillosis 83 (76.8%)
Invasive sinus or CNS aspergillosis 5 (4.6%)
Invasive candidal infection 9 (8.3%)
Other invasive fungal infectionδ 13 (12.0%)
Febrile neutropenia 9 (8.3%)
Diagnosis of infection
Proven or probable invasive fungal
disease
46 (42.5%)
Possible invasive fungal disease 43 (39.8%)
Voriconazole initial drug level
Subtherapeutic (<1.0 mg/L) 32 (29.6%)
Therapeutic (1.0-5.5 mg/L) 64 (59.2%)
Supratherapeutic (>5.5 mg/L) 12 (11.1%)
*Sixteen patients received voriconazole therapy for more than one indication.
δ Other fungal organisms included Fusarium (n = 2), Absidia (n = 1), Alternaria
(n = 1), Saccharomyces (n = 1), Scedosporium (n = 1), Ascomyctes (n = 1),
Rhizopus (n = 1), Pseudoallescheria (n = 1), and Paecilomyces (n = 1).
Table 2 Voriconazole dosing characteristics, drug level
monitoring, and duration of therapy
Voriconazole therapy Median value
[(IQR]
Voriconazole serial drug levels (mg/L)
Initial drug level (n = 108) 2.35 [0.7, 3.8]
Second drug level (n = 51) 2.00 [0.5, 3.5]
Third drug level (n = 26) 1.35 [0.6, 7.7]
Voriconazole loading dose (mg/dose; n = 59) 400 [350, 480]
Voriconazole maintenance dose (mg/dose; n = 107) 260 [200,300]
Patient weight (kg; n = 107) 71.3 [60.5, 85.8]
Duration of voriconazole therapy in days (n = 85) 35 [13, 92]
Days between initiation of voriconazole to first drug
level (n = 100)
11 [3,164]
Hours between last dose and trough drug level
(n = 64)
11.3 [8.9-12.0]
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response to therapy at 12 weeks and 11 (23.9%) had dis-
ease progression (Table 3). Among patients with proven
and probable disease, there was no significant relationship
between therapeutic drug levels and achievement of
complete or partial response at 12 weeks (Figure 3; OR
0.29, 95% CI: 0.05-1.34) although we did observe a signifi-
cant relationship between subtherapeutic initial drug levels
and achievement of complete or partial response at
6 weeks (OR 0.19, 95% CI 0.04-0.96). Among those with
pulmonary aspergillosis, radiologic response, as defined by
decrease in size of pulmonary nodules on CT scan, was
noted in 37/67 (55.2%). There was no significant rela-
tionship between therapeutic drug levels and radiologic
response (OR 1.46, 95% CI: 0.32-7.83). We further ex-
amined the subset of patients who had complete or par-
tial response at 6 weeks with initial subtherapeutic drug
levels. Of these, all seven had invasive pulmonary aspergil-
losis. Three were stem cell transplant recipients, two had
received lung transplants, one had chronic obstructive
























Figure 1 Comparison of median voriconazole drug levels. Median voriconazole drug level did not vary by first, second or third drug level
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Voriconazole Drug Level by Initial Dose
Figure 2 Comparison of voriconazole initial drug level by weight-adjusted dosage received. Initial drug level did not correlate with
weight-adjusted dosage of voriconazole (r2 = 0.01; n = 107). Area between the horizontal lines indicates the therapeutic range between 1.0
and 5.5 mg/L.
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immunodeficiency syndrome. The median time between
start of voriconazole therapy and monitoring was seven
days (range, 4–26 days). Of the four patients who had a
repeat level checked, two remained subtherapeutic and
two had a therapeutic level.
We examined for the presence of confounders in
patients with and without therapeutic drug levels,
and found no statistically significant baseline differ-
ences in gender, steroid use, duration of voriconazole
therapy, obesity (defined as weight ≥ 90 kg), duration
of neutropenia ≥ 10 days, presence of graft-versus-host-
disease, or use of combination antifungals.
Among all patients, we recorded adverse events in the
time period within the first month of therapy or the
duration of hospitalization, whichever was longer. We
observed 45 (41.7%) adverse events with 21 cases of en-
cephalopathy and 15 cases of hepatotoxicity (Table 4,
Figure 4). Among the 15 cases of hepatotoxicity, only two
received initial doses greater than 4 mg/kg. Voriconazole
levels > 5.5 mg/L at any time during therapy (n = 16) were
not associated with the overall occurrence of adverse
events (OR 2.00; 95% CI 0.60-6.89). Specifically, there
was no significant association between supratherapeutic
levels and hepatotoxicity (OR 2.45; 95% CI: 0.49-10.0)
Table 3 The relationship between voriconazole initial drug levels and clinical and radiologic response to therapy at 6





OR [95% CI] p-value
Intravenous maintenance dose administration 11 (35.4%) 26 (36.1%) 1.02 [0.39-2.77] 0.95†
Voriconazole median dosage (mg) 280 (170–400) 255 (125–480) – 0.61‡
Response to antifungal therapy at 6 weeks*
Complete or partial response (n = 13) 7/13 (53.8%) 6/33 (18.2%) 0.19 [0.04-0.96] 0.03 §
Progression of disease (n = 9) 1/13 (7.7%) 8/33 (24.2%) 3.84 [0.42-184.3] 0.41 §
Response to antifungal therapy at 12 weeks*
Complete or partial response (n = 22) 9/13 (69.2%) 13/33 (39.4%) 0.29 [0.05-1.34] 0.10 §
Progression of disease (n = 11) 3/13 (23.1%) 8/33 (24.2%) 1.07 [0.20-7.50] 1.00 §
Radiologic improvement*
Pulmonary nodule resolution or decrease in size at 6 weeks
(n = 46)
4 (30.8%) 13 (39.4%) 1.46 [0.32-7.83] 0.74 §
* In patients with proven or probable invasive fungal disease (n = 46).
† Chi-squared test.
‡ Two-sample t-test.
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Figure 3 Cumulative incidence graph comparing therapy response with therapeutic versus subtherapeutic initial drug levels shows no
statistically significant difference in complete or partial response to therapy at 12 weeks among a subset of patients with proven or
probable invasive fungal disease (n = 46; HR: 0.45; P = 0.07).
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or encephalopathy (OR 3.08; 95% CI: 0.79-11.0). There
was significantly more acute renal failure in patients
with supratherapeutic drug levels (OR 7.33; 95% CI
1.17-43.8). Patients with and without supratherapeutic
drug levels did not differ in baseline creatinine prior to
start of voriconazole or in use of the intravenous formula-
tion of voriconazole. There were no significant differences
in presence of visual changes or drug rash between the
two groups.
Discussion
In our patient population, the majority of patients receiv-
ing drug monitoring had hematologic malignancy and pre-
sumptive invasive aspergillosis, although fewer than half
(n = 46; 43%) had proven or probable invasive fungal dis-
ease. Consistent with prior studies, there was high variabil-
ity in initial drug levels, and those levels did not correlate
with voriconazole dosage [8,15,24,25]. The time be-
tween initiation of voriconazole and initial drug level
was 11 days in our study. Despite the long duration be-
tween drug initiation and TDM, one-third of our patients
had subtherapeutic initial drug levels. When we compared
dosing regimens in patients with levels < 1.0 mg/L to those
with levels ≥ 1.0 mg/L, we found no difference in the pro-
portion who received intravenous formulations or weight-
adjusted dosage, suggesting that weight and route of
administration are not the primary determinants of drug
levels [26,27].
Furthermore, similar to prior studies, we found that
the majority of patients who had subtherapeutic or su-
pratherapeutic levels on initial testing had similar subse-
quent results. Because of the nature of our study, we do
not have data regarding the presence of genetic polymor-
phisms that affect drug metabolism such as CYP2C19 in
Table 4 The relationship between supratherapeutic voriconazole drug levels during therapy and adverse drug events
Variable Voriconazole level
≤ 5.5 mg/L (n = 92)
Voriconazole level
> 5.5 mg/L (n = 16)
OR [95% CI]
Any adverse drug event* 36 (39.1%) 9 (56.3%) 2.00 [0.60-6.89]†
Adverse drug event by subtype*
Encephalopathy 15 (16.3%) 6 (37.5%) 3.08 [0.79-11.0]†
LFT abnormalities (AST/ALT > 5x ULN, Alk phos/bili >3x ULN) 11 (12.0%) 4 (25.0%) 2.45 [0.49-10.1]†
Acute renal failure (creatinine rise≥ 0.3 mg/L in 48 hours)§ 4 (4.3%) 4 (25.0%) 7.33 [1.17-43.8]†
Visual changes 5 (5.4%) 0 (0%) –
Drug rash 6 (6.5%) 1 (6.3%) 0.96 [0.02-8.81]†
*For at least one month after initiation of therapy.
†Fisher’s exact test.
























































Comparison of Frequency of Adverse Drug Events by Drug Level 
Drug Level < 5.5 mg/L 
Drug Level > 5.5 mg/L 
Figure 4 Comparison of frequency of adverse drug events in patients with and without supratherapeutic drug levels, defined as a
level > 5.5 mg/L. The y-axis represents the percentage of patients with adverse drug events. The total number of adverse drug events, as well as
individual drug events, are noted on the x-axis. There was no statistically significant difference in the frequency of overall adverse drug events, or
of encephalopathy, hepatoxicity, skin rash, or visual changes among patients with and without supratherapeutic voriconazole drug levels. There
was a statistically significant difference in incidence of acute renal failure (*) between the two groups.
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our population that could explain some of the variability
in initial drug levels [15,28,29]. A further analysis of clin-
ical and radiologic outcomes among the patients who
were Caucasian, in whom the CYP2C19 polymorphism is
more prevalent, did not reveal any difference in associa-
tions between drug level and outcome as compared to
the total study population. It is also possible that for a
subset of our patients, voriconazole drug levels are not
reflective of true trough concentrations because of in-
appropriate timing of drug level monitoring relative to
voriconazole dose administration. This may be particu-
larly true among outpatients for whom we do not have
information regarding dosage in relationship to drug
level monitoring. In prior studies, there has been high
variability in physician ordering practices of voriconazole
levels, including random drug levels being checked rather
than true trough levels [30]. In our study, however, we
found that the median time after dose administration
was close to ideal at 11.3 hours. Nonadherence to ther-
apy is also a factor that is associated with subtherapeutic
drug levels, and has been examined in prior studies by
measuring presence of voriconazole metabolites in pa-
tient blood samples [15]. These factors are less likely to
be the case in our study given clear documentation of the
timing of dose administration and blood sample collec-
tion among our inpatients, though this data is often
incomplete for our outpatient population.
No significant relationship between achievement of
therapeutic drug levels and clinical response to therapy at
12 weeks or radiologic response was demonstrated among
patients with proven or probable invasive fungal infection.
Surprisingly, at 6 weeks, there was a significant association
between subtherapeutic drug levels and clinical response.
These results are in contrast to prior studies, which do
show a relationship between therapeutic drug levels and
clinical efficacy [7,10,11]. This discrepancy may be a result
of limiting our analysis of clinical outcomes to patients
with proven or probable IFIs. Prior studies have examined
clinical response in all patients with voriconazole TDM,
including those without proven or probable IFI [10]. In
addition, the timing of clinical outcome assessment may
have been different from prior studies, as well as the
sociodemographic profile of the patient population [31].
We chose to perform our assessment at 6 and 12 weeks,
rather than at 2 weeks, due to the prolonged period of
immunosuppression and duration of antifungal therapy in
many of our patients.
An important potential selection bias in our study was
the selective inclusion of patients for whom voriconazole
TDM was performed. There were many patients who re-
ceived voriconazole who did not have their levels moni-
tored, and we were unable to capture data on these
patients. The decision to order voriconazole levels was at
the discretion of the clinician. An algorithm was put into
place for routine ordering of voriconazole levels, though
this was not implemented until early 2009, and did not
affect most of the patients whom we studied. We have,
however, attempted to address the bias by performing the
evaluation of clinical outcome only among patients with
proven and probable invasive fungal infection, for whom
initial voriconazole TDM was likely to be performed re-
gardless of response to therapy. However, selection bias
could potentially explain why we did not show a relation-
ship between achievement of therapeutic drug levels and
clinical response.
We were limited in our study by an inability to capture
mortality data, given the retrospective nature of the chart
review and the loss to follow-up among some inpatients
who transitioned to outpatient care. However, for the ma-
jority of patients, we were able to obtain outcomes mea-
sured at 6 and 12 weeks after initiation of voriconazole
therapy, and we have based our analysis on these end-
points. We also do not have information on the microbio-
logic isolates of the pathogens to establish the relationship
between voriconazole serum concentration and pathogen
MICs, as performed in prior studies because this was not
routinely performed at our institution in 2007–2009
[32,33]. We explored whether differences in confounders
between patients with subtherapeutic and therapeutic
levels could account for the difference in therapeutic out-
come. We did not find differences between the two groups
in weight, steroid use, incidence of graft-versus-host-dis-
ease, duration of therapy, or use of combination antifungal
agents. We were unable to evaluate the effect of sepsis
as a potential confounder because many of our patients
had prolonged complicated hospitalizations related to
their hematologic malignancies, and it was difficult to
determine whether sepsis during their hospitalization
had an effect on their voriconazole concentrations. We
speculate that in our population with a high proportion of
patients with hematologic malignancy and hematopoietic
stem cell transplantation, host immune response is an im-
portant predictor of outcome.
There is currently no consensus on optimal timing for
voriconazole drug monitoring. It is unclear whether rou-
tine voriconazole drug monitoring should be performed,
or whether the clinical utility of TDM is limited to pa-
tients with adverse events. The study by Dolton et al. in-
cluded all patients for whom trough levels were checked
on day 2 of dosing in those with loading doses, and on day
7 or later in those without loading doses [34]. All of our
patients had drug monitoring performed at least 3 days
after initiation of therapy, suggesting that they had reached
a steady-state level by time of monitoring.
A high frequency of adverse drug events was seen in our
patient population, with a higher incidence of acute renal
failure in patients with supratherapeutic levels. Despite
prior reports associating cyclodextrin in intravenous
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formulations with renal failure [17], we did not find a dif-
ference in prevalence of intravenous dose administration
between patients who did and did not have renal failure.
We also found no association between supratherapeutic
levels and hepatotoxicity, in contrast to prior studies
which have noted significantly higher levels of liver func-
tion test abnormalities with higher trough levels [11,29].
Also, we did not find that the patients with hepatotoxicity
received doses higher than the standard 4 mg/kg dosing,
consistent with prior data showing that higher doses do
not correspond to hepatoxicity [5]. Similar to prior stud-
ies, a trend suggesting that supratherapeutic voriconazole
levels were associated with encephalopathy was seen,
though this was not a statistically significant association
[18]. It is possible that the nature of the chart review did
not allow us to capture information regarding the pres-
ence of central nervous system effects because it relied
on provider charting of symptoms. However, overall our
population had rates of adverse events similar to prior
studies suggesting that despite use of chart review for
data extraction, we were able to capture a substantial
proportion of the adverse events experienced by our
patients [35].
Our results stand in contrast to a recent randomized
controlled trial conducted at a single center in Korea
showing improvement in clinical outcomes and decrease
in discontinuation of therapy due to adverse events with
therapeutic drug monitoring [20]. We believe that this
reflects both a difference in our patient population and
the absence of a clinical trial design in our study. Partici-
pation in clinical trials may change the behavior of phy-
sicians and patients, and results are often difficult to
replicate in clinical practice [36]. Our study reflects the
outcomes seen in practice at an academic center highly
experienced with management of invasive fungal infec-
tions in immunocompromised hosts. We propose that
further studies be performed to evaluate whether imple-
mentation of the clinical trial algorithm is efficacious in
a clinical setting.
Conclusions
In conclusion, we observed that in clinical practice, moni-
toring of voriconazole therapeutic drug levels did not have
any effect on adverse events or on clinical outcomes in a
population with a high rate of hematologic malignancy
and invasive fungal infections. We suggest that further
prospective studies should be performed to evaluate the
relationship between drug levels and therapeutic efficacy
at multiple centers. These studies should include an evalu-
ation of adherence to TDM monitoring algorithms, and
aim to identify the particular subset of patients for whom
drug monitoring yields benefits in terms of clinical efficacy
and avoidance of adverse drug events.
Competing interests
All authors declare no conflicts of interest.
Authors’ contributions
All authors contributed to the work presented in this paper. HC, RJ, PP, and
DF jointly conceived the study. HC designed the study, gathered the data
and performed statistical analysis with assistance from HX. HC wrote the
manuscript with contributions from other authors. HX performed the
statistical analysis. RJ, DF, and PP gave conceptual advice and technical
support. All authors discussed the results and implications and commented
on the manuscript at all stages. All authors read and approved the final
manuscript.
Author details
1Division of Allergy & Infectious Diseases, Department of Medicine, University
of Washington, Seattle, WA, USA. 2Department of Pharmacy, University of
Washington Medical Center, Seattle, WA, USA. 3Vaccine and Infectious
Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Received: 17 April 2012 Accepted: 19 February 2013
Published: 26 February 2013
References
1. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA,
Morrison VA, Segal BH, Steinbach WJ, Stevens DA, et al: Treatment of
aspergillosis: clinical practice guidelines of the Infectious Diseases
Society of America. Clin Infect Dis 2008, 46(3):327–360.
2. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A,
Ruhnke M, Lode H: Efficacy and safety of voriconazole in the treatment
of acute invasive aspergillosis. Clin Infect Dis 2002, 34(5):563–571.
3. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann
JW, Kern WV, Marr KA, Ribaud P, Lortholary O, et al: Voriconazole versus
amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med
2002, 347(6):408–415.
4. Pea F, Viale P: Hallucinations during voriconazole therapy: who is at
higher risk and could benefit from therapeutic drug monitoring?
Ther Drug Monit 2009, 31(1):135–136.
5. Gorski E, Esterly JS, Postelnick M, Trifilio S, Fotis M, Scheetz MH: Evaluation
of hepatotoxicity with off-label oral-treatment doses of voriconazole for
invasive fungal infections. Antimicrob Agents Chemother 2011,
55(1):184–189.
6. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X,
Vora AJ, Arrieta AC, Blumer J, Lutsar I, et al: Pharmacokinetics and safety of
intravenous voriconazole in children after single- or multiple-dose
administration. Antimicrob Agents Chemother 2004, 48(6):2166–2172.
7. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG,
Andes D: Voriconazole therapeutic drug monitoring. Antimicrob Agents
Chemother 2006, 50(4):1570–1572.
8. Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Decosterd LA, Buclin T,
Majcherczyk PA, Sanglard D, Marchetti O: Variability of voriconazole
plasma levels measured by new high-performance liquid
chromatography and bioassay methods. Antimicrob Agents Chemother
2007, 51(1):137–143.
9. Chen J, Chan C, Colantonio D, Seto W: Therapeutic drug monitoring of
voriconazole in children. Ther Drug Monit 2012, 34(1):77–84.
10. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O: Voriconazole
therapeutic drug monitoring in patients with invasive mycoses improves
efficacy and safety outcomes. Clin Infect Dis 2008, 46(2):201–211.
11. Mitsani D, Nguyen MH, Shields RK, Toyoda Y, Kwak EJ, Silveira FP, Pilewski
JM, Crespo MM, Bermudez C, Bhama JK, et al: A prospective, observational
study of voriconazole therapeutic drug monitoring among lung
transplant recipients receiving prophylaxis: Factors impacting levels and
associations between serum troughs, efficacy and toxicity.
Antimicrob Agents Chemother 2012, 56(5):2371–2377.
12. Hussaini T, Ruping MJ, Farowski F, Vehreschild JJ, Cornely OA: Therapeutic
drug monitoring of voriconazole and posaconazole. Pharmacotherapy
2011, 31(2):214–225.
13. Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ: Voriconazole
Pharmacokinetics and Therapeutic Drug Monitoring: A Multi-Center
Study. Antimicrob Agents Chemother 2012, 56(9):4793–4799.
Chu et al. BMC Infectious Diseases 2013, 13:105 Page 8 of 9
http://www.biomedcentral.com/1471-2334/13/105
14. Johnson HJ, Han K, Capitano B, Blisard D, Husain S, Linden PK, Marcos A,
Kwak EJ, Potoski B, Paterson DL, et al: Voriconazole pharmacokinetics in
liver transplant recipients. Antimicrob Agents Chemother 2010,
54(2):852–859.
15. Hassan A, Burhenne J, Riedel KD, Weiss J, Mikus G, Haefeli WE, Czock D:
Modulators of very low voriconazole concentrations in routine
therapeutic drug monitoring. Ther Drug Monit 2011, 33(1):86–93.
16. Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A:
Impact of therapeutic drug monitoring of voriconazole in a pediatric
population. Pediatr Infect Dis J 2011, 30(6):533–534.
17. Hafner V, Czock D, Burhenne J, Riedel KD, Bommer J, Mikus G, Machleidt C,
Weinreich T, Haefeli WE: Pharmacokinetics of sulfobutylether-beta
-cyclodextrin and voriconazole in patients with end-stage renal failure
during treatment with two hemodialysis systems and hemodiafiltration.
Antimicrob Agents Chemother 2010, 54(6):2596–2602.
18. Imhof A, Schaer DJ, Schanz U, Schwarz U: Neurological adverse events to
voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly
2006, 136(45–46):739–742.
19. Dolton MJ, Ray JE, Marriott D, McLachlan AJ: Posaconazole exposure-
response relationship: evaluating the utility of therapeutic drug
monitoring. Antimicrob Agents Chemother 2012, 56(6):2806–2813.
20. Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ: Multicenter study
of posaconazole therapeutic drug monitoring: exposure-response
relationship and factors affecting concentration. Antimicrob Agents
Chemother 2012, 56(11):5503–5510.
21. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T,
Pappas PG, Maertens J, Lortholary O, Kauffman CA, et al: Revised definitions
of invasive fungal disease from the European Organization for Research
and Treatment of Cancer/Invasive Fungal Infections Cooperative Group
and the National Institute of Allergy and Infectious Diseases Mycoses
Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008,
46(12):1813–1821.
22. Langman LJ, Boakye-Agyeman F: Measurement of voriconazole in serum
and plasma. Clin Biochem 2007, 40(18):1378–1385.
23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: Research
electronic data capture (REDCap)–a metadata-driven methodology and
workflow process for providing translational research informatics
support. J Biomed Inform 2009, 42(2):377–381.
24. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S,
Winter J, Tallman M, et al: Monitoring plasma voriconazole levels may be
necessary to avoid subtherapeutic levels in hematopoietic stem cell
transplant recipients. Cancer 2007, 109(8):1532–1535.
25. Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J: Serial plasma
voriconazole concentrations after allogeneic hematopoietic stem cell
transplantation. Antimicrob Agents Chemother 2009, 53(5):1793–1796.
26. Dickmeyer NJ, Kiel PJ: Dosing voriconazole in an obese patient.
Clin Infect Dis 2011, 53(7):745.
27. Pai MP, Lodise TP: Steady-state plasma pharmacokinetics of oral
voriconazole in obese adults. Antimicrob Agents Chemother 2011,
55(6):2601–2605.
28. Kimura M, Yamagishi Y, Kawasumi N, Hagihara M, Hasegawa T, Mikamo H:
[Clinical implication of therapeutic drug monitoring on voriconazole
from the aspect of the analysis for CYP2C19 gene]. Jpn J Antibiot 2010,
63(3):255–264.
29. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, Zembower T, Mehta J:
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic
stem cell transplant recipients. Bone Marrow Transplant 2005,
35(5):509–513.
30. Miyakis S, van Hal SJ, Solvag CJ, Ray J, Marriott D: Clinician ordering
practices for voriconazole therapeutic drug monitoring: experiences of a
referral laboratory. Ther Drug Monit 2010, 32(5):661–664.
31. Lee YJ, Lee SO, Choi SH, Kim YS, Woo JH, Chun S, Kim DY, Lee JH, Lee JH,
Lee KH, et al: Initial voriconazole trough blood levels and clinical
outcomes of invasive aspergillosis in patients with hematologic
malignancies. Med Mycol 2012:1–7. Early Online.
32. Troke PF, Hockey HP, Hope WW: Observational study of the clinical
efficacy of voriconazole and its relationship to plasma concentrations in
patients. Antimicrob Agents Chemother 2011, 55(10):4782–4788.
33. Szabo Z, Borbely A, Kardos G, Somogyvari F, Kemeny-Beke A, Asztalos L,
Rozgonyi F, Majoros L: In vitro efficacy of amphotericin B, 5-
fluorocytosine, fluconazole, voriconazole and posaconazole against
Candida dubliniensis isolates using time-kill methodology. Mycoses 2010,
53(3):196–199.
34. Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ: Multicenter
study of voriconazole pharmacokinetics and therapeutic drug
monitoring. Antimicrob Agents Chemother 2012, 56(9):4793–4799.
35. Kim SH, Yim DS, Choi SM, Kwon JC, Han S, Lee DG, Park C, Kwon EY, Park
SH, Choi JH, et al: Voriconazole-related severe adverse events: clinical
application of therapeutic drug monitoring in Korean patients.
Int J Infect Dis 2011, 15(11):e753–758.
36. Godwin M, Ruhland L, Casson I, MacDonald S, Delva D, Birtwhistle R, Lam M,
Seguin R: Pragmatic controlled clinical trials in primary care: the struggle
between external and internal validity. BMC Med Res Methodol 2003, 3:28.
doi:10.1186/1471-2334-13-105
Cite this article as: Chu et al.: Voriconazole therapeutic drug monitoring:
retrospective cohort study of the relationship to clinical outcomes and
adverse events. BMC Infectious Diseases 2013 13:105.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chu et al. BMC Infectious Diseases 2013, 13:105 Page 9 of 9
http://www.biomedcentral.com/1471-2334/13/105
